1. Scrip
  2. >>Business
  3. >>Earnings

Bristol’s Growth Plan Faces First Test In 2022

New Drugs Hit $1bn Mark In 2021, But First Revlimid Generics Launch This Year

 
• By Mandy Jackson

Zeposia, Reblozyl, Breyanzi and Abecma turned BMS’s new product portfolio into a blockbuster revenue stream last year to help fill the $3.5bn gap created by Revlimid and Abraxane generics.

Set of Three Increasing Size Red and White Cartoon Spaceships on Dark Background
BMS will launch three new products, pending approvals, in the US in 2022 • Source: Alamy

Bristol Myers Squibb Company spent the past year laying out its plan for growth through the end of this decade as its three top-selling products lose exclusivity. While 2022 will be the first year that the company’s strategy is put to the test as Revlimid (lenalidomide) faces its first generic competition, the contribution of new product launches to Bristol’s revenue in 2021 suggests that plan is off to a good start.

BMS reported on 4 February that its full-year 2021 product sales totaled $46.4bn, up 9% from 2020, including $12bn in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Finance Watch: Insmed Cashes In On Positive Data With $750m Offering

 
• By Mandy Jackson

Public Company Edition: Insmed raised $750m after reporting positive Phase IIb data in PAH, Cogent accessed up to $400m in new debt, Kelun-Biotech netted $250m in a placement of shares and ADC revealed a $100m private placement. In strategic updates, Recursion cut 20% of its jobs.

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

 
• By Joseph Haas

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.

Asia Deal Watch: Otsuka’s Taiho Licenses LSD1 Inhibitor Rights To Benz

 
• By Joseph Haas, Lisa Takagi, Jung Won Shin, Vibha Ravi, and Sushmita Panda

Plus deals involving BioAge/JiKang, Sanyou/Medicovestor, AriBio/Acino, Intragrand/Transpire, Kaken/Twocells, Sumitomo/Novo Nordisk, NIBEC/Undisclosed, Formosa/Adalvo, Drug Farm/Amoytop, Lupin/SteinCares and Lupin/Honeywell.